LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

Search

Charles River Laboratories International Inc

Chiusa

SettoreSettore sanitario

157.32 -2.31

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

157.32

Massimo

163.84

Metriche Chiave

By Trading Economics

Entrata

2.9M

56M

Vendite

-27M

1B

EPS

2.43

Margine di Profitto

5.529

Dipendenti

18,700

EBITDA

-23M

198M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+45.8% upside

Dividendi

By Dow Jones

Utili prossimi

18 feb 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-862M

7.9B

Apertura precedente

159.63

Chiusura precedente

157.32

Notizie sul Sentiment di mercato

By Acuity

100%

0%

341 / 351 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Charles River Laboratories International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

17 feb 2026, 23:44 UTC

Azioni calde

Stocks to Watch: La-Z-Boy, Palo Alto Networks, Caesars

17 feb 2026, 23:20 UTC

Utili

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps -- Update

17 feb 2026, 22:57 UTC

Utili

Santos Fiscal Year Net Profit Falls 33%, Nears Start of Alaska Project

17 feb 2026, 21:59 UTC

Utili

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps

17 feb 2026, 23:54 UTC

Discorsi di Mercato

Nikkei May Rise as Fears About AI Disruption Ease -- Market Talk

17 feb 2026, 23:54 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

17 feb 2026, 23:54 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

17 feb 2026, 23:45 UTC

Discorsi di Mercato

Suncorp's Outperformance of IAG Could Be Hard to Sustain -- Market Talk

17 feb 2026, 23:19 UTC

Utili

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

17 feb 2026, 23:15 UTC

Utili

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

17 feb 2026, 22:58 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Netflix Would Operate Warner's Studios, HBO Largely the Same -- Market Talk

17 feb 2026, 22:58 UTC

Acquisizioni, Fusioni, Takeovers

BlueScope Steel: Board Committed to Optimizing Value For Shareholders

17 feb 2026, 22:57 UTC

Acquisizioni, Fusioni, Takeovers

BlueScope Steel to Consider Revised SGH, Steel Dynamics Takeover Bid

17 feb 2026, 22:50 UTC

Acquisizioni, Fusioni, Takeovers

Agnico-Eagle Mines Acquired 662,780 Common Shrs of Maple Gold Mines at C$2.45 Per Common Shr >AEM.T

17 feb 2026, 22:44 UTC

Utili

Palo Alto Reports Strong Earnings. Its Stock Is Down. -- Barrons.com

17 feb 2026, 22:42 UTC

Utili

Santos FY Net Profit Falls 33%, Nears Start of Alaska Project

17 feb 2026, 22:36 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Netflix Sarandos: Paramount Causing Confusion Around Warner Deal -- Market Talk

17 feb 2026, 22:36 UTC

Utili

Santos Final Dividend 10.3 U.S. Cents/Security

17 feb 2026, 22:36 UTC

Utili

Santos FY Underlying Profit US$898 Million, Down 25%

17 feb 2026, 22:35 UTC

Utili

Santos FY Revenue US$4.94 Billion, Down 8%

17 feb 2026, 22:35 UTC

Utili

Correct: Santos FY Net Profit US$818 Million, Down 33%

17 feb 2026, 22:35 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Buys New York Times Stock; Sells Apple, Bank of America, Amazon In 4Q -- Barrons.com

17 feb 2026, 22:34 UTC

Utili

Santos FY Net Profit US$818 Billion, Down 33%

17 feb 2026, 22:02 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Pares Stakes in Apple and BofA, Adds New York Times Position -- Update

17 feb 2026, 21:50 UTC

Acquisizioni, Fusioni, Takeovers

Steel Dynamics: SGH Would Buy BlueScope, On-sell North American Operations to SDI, As Earlier Proposed

17 feb 2026, 21:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Tech, Media & Telecom Roundup: Market Talk

17 feb 2026, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

17 feb 2026, 21:49 UTC

Acquisizioni, Fusioni, Takeovers

Steel Dynamics Says Revised Proposal Continues to Present Highly Strategic Opportunity For SDI Shareholders

17 feb 2026, 21:48 UTC

Acquisizioni, Fusioni, Takeovers

Steel Dynamics: BlueScope Offer a 56% Premium to 52-Week Volume Weighted Average Price

17 feb 2026, 21:48 UTC

Acquisizioni, Fusioni, Takeovers

Steel Dynamics: Consideration To Be Comprised Entirely of Cash

Confronto tra pari

Modifica del prezzo

Charles River Laboratories International Inc Previsione

Obiettivo di Prezzo

By TipRanks

45.8% in crescita

Previsioni per 12 mesi

Media 235.25 USD  45.8%

Alto 265 USD

Basso 190 USD

Basato su 10 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

10 ratings

8

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

117.16 / 144.77Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

341 / 351 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat